2008
DOI: 10.1038/sj.onc.1211031
|View full text |Cite
|
Sign up to set email alerts
|

Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
16
0
2

Year Published

2008
2008
2023
2023

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(19 citation statements)
references
References 42 publications
1
16
0
2
Order By: Relevance
“…Furthermore, previous studies showed that LDM chemotherapy alone sometimes resulted in transient tumor growth inhibition, increased hypoxia, and finally stimulated tumor growth [31]. It is reported that metronomic cisplatinum chemotherapy can cause such changes as an increase in endothelial cell VEGF or enhanced expression of tumor cell-associated EGFR, either of which could promote tumor growth.…”
Section: Discussionmentioning
confidence: 98%
“…Furthermore, previous studies showed that LDM chemotherapy alone sometimes resulted in transient tumor growth inhibition, increased hypoxia, and finally stimulated tumor growth [31]. It is reported that metronomic cisplatinum chemotherapy can cause such changes as an increase in endothelial cell VEGF or enhanced expression of tumor cell-associated EGFR, either of which could promote tumor growth.…”
Section: Discussionmentioning
confidence: 98%
“…16 According to our findings, the ischemia that a solid tumor is commonly subjected to 34 is helping to drive epigenetic disruption. Anti-angiogenic drugs designed to cut off blood supply to tumors may also be accelerating ischemia in solid tumors 41 and as a result these therapies may unintentionally alter epigenetic processes. If the tumor microenvironment is modifying DNMT expression and activity, therapies targeted at inhibiting DNMT1 may not be effective if DNMT1 levels or activity are already being reduced by ischemic conditions.…”
Section: Ink4amentioning
confidence: 99%
“…Однако в каждой работе приводятся данные о пациентах с длительной стабилизацией на терапии с включением пероральной формы цикло-фосфана, что, возможно, связано с молекулярным подтипом опухоли. Так, в эксперименте на ксено-графтных моделях рака толстой кишки эффект от мет-рономного воздействия циклофосфаном наблюдался в отношении опухолей с мутацией в гене KRAS [71].…”
Section: Discussionunclassified
“…Темозоломид -алкилирующий препарат II поко-ления, относящийся к классу имидазотетразинов, обладающий высокой биодоступностью и способно-стью проникать через гематоэнцефалический барьер [64,[70][71][72][73]. В метрономных режимах применяется обычно в дозе 75 мг / м 2 , хотя дозировки варьируют по данным различных исследований [65,74].…”
Section: механизм противоопухолевого действия метрономной химиотерапииunclassified